Skip to Main Content

A U.S. appeals panel on Wednesday denied a patent challenge against Biogen’s multiple sclerosis drug Tecfidera, putting off the early launch of a generic version by Mylan and sending shares of Biogen surging.

Mylan, the generic drug maker, had filed an inter partes review seeking to overturn the last remaining patent on Tecfidera, Biogen’s most important multiple sclerosis drug. That patent was not set to expire until 2028.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • I have just learned that Tecfidera is dimethyl fumarate. That is, an off patent cheap chemical that can be bought from chemical suppliers at a whopping 100$ for 100g, good for about 200 daily doses. Or, less than 200$/year instead of 60K/year.
    Once again, a pathetically “innovative” drug and an FDA validated scam

Comments are closed.